We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Are There Differences in Efficacy and Safety Between 2nd-Generation Drug-Eluting Stents for Left Main Coronary Intervention?
- Authors
Hirai, Taishi; Blair, John E. A.
- Abstract
Objective. To compare the effectiveness and safety profiles of various second-generation drugeluting stents (DES) for left main coronary intervention. Design. Retrospective study using 3 multicenter prospective registries (IRIS-DES, IRIS-MAIN, PRECOMBAT). Setting and participants. Among the 4470 patients enrolled in the 3 registries treated between July 2007 and July 2015, the authors identified 2692 patients with significant left main coronary artery disease who received second-generation DES for inclusion in the study. The centers for IRIS-DES and PRECOMBAT are academic and community hospitals in South Korea, with IRISMAIN involving academic and community hospitals in South Korea, China, India, Indonesia, Japan, Malaysia, Taiwan, and Thailand. Of the patients in these registries, 1254 received cobaltchromium everolimus-eluting stents (CoCr-EES), 232 biodegradable polymer biolimus-eluting stents (BP-BES), 616 platinum-chromium EES (PtCr-EES) and 590 Resolute zotarolimus-eluting stents (Re-ZES). Main outcome measure. Target-vessel failure. Main results. At 3 years, rates of target-vessel failure were not significantly different for the different types of stents (16.7% for the CoCr-EES, 13.2% for the BP-BES, 18.7% for the PtCr-EES, and 14.7% for the Re-ZES; P = 0.15). The adjusted hazard ratios (HRs) for target-vessel failure were similar in between-group comparisons of the different stents, except for the PtCr-EES versus the BP-BES (HR 1.60, 95% confidence interval 1.01 to 2.54; P = 0.046). There were no significant differences in risk of composite of all-cause death, any myocardial infarction, or any revascularization and its individual components according to the different types of stents. Conclusion. There was no significant between-group differences in 3-year risk of target-vessel failure, except for a higher risk of primary outcome with PtCr-EES compared to BP-BES.
- Subjects
CORONARY heart disease treatment; DRUG-eluting stents; CORONARY disease; SAFETY; TREATMENT effectiveness; PERCUTANEOUS coronary intervention; STANDARDS
- Publication
Journal of Clinical Outcomes Management, 2018, Vol 25, Issue 7, p298
- ISSN
1079-6533
- Publication type
Article